Valeant Offers to Buy Botox Maker Allergan

April 22 (Bloomberg) -- Valeant Pharmaceuticals International offered to buy Allergan for about $152.89 a share in a cash-and-stock deal that will give the Canadian company the Botox wrinkle treatment. Scarlet Fu reports on Bloomberg Television’s “Bloomberg Surveillance.” (Source: Bloomberg)

What Companies Link CEO Pay to Being Green?
17:50 - Bloomberg's Anders Melin reports on tying company CEO paychecks to carbon emissions. He speaks on "Bloomberg Markets." (Source: Bloomberg)
  • David Bahnsen's Investment Ideas for 2016
  • How Will Markets React to Yuan in IMF Reserve Currency?
  • Just How Successful Is Prime for Amazon?